Invention Grant
- Patent Title: Monoclonal antibodies against the active site of factor XI and uses thereof
-
Application No.: US16087686Application Date: 2017-03-23
-
Publication No.: US11059905B2Publication Date: 2021-07-13
- Inventor: Péter Boross , Cafer Yildiz , Cornelis Erik Hack
- Applicant: Prothix B.V.
- Applicant Address: NL Leiden
- Assignee: Prothix B.V.
- Current Assignee: Prothix B.V.
- Current Assignee Address: NL Leiden
- Agency: N.V. Nederlandsch Octrooibureau
- Agent Tamara C. Stegmann; Catherine A. Shultz
- Priority: NL2016477 20160323
- International Application: PCT/EP2017/056924 WO 20170323
- International Announcement: WO2017/162791 WO 20170928
- Main IPC: C07K16/36
- IPC: C07K16/36 ; A61P7/02 ; C12N15/62 ; A61K39/00
Abstract:
The present invention provides novel anti-factor XI (FXI) antibodies and compositions comprising such antibodies. The anti-FXI antibodies of the invention specifically bind to the active center of FXI and inhibit the functional activity of FXI. The invention further provides humanized versions of the anti-FXI antibodies that are useful in the prevention and treatment of conditions in which pathological thrombus formation or thrombo-embolism are involved. The invention further provides nucleic acid molecules encoding the anti-FXI antibodies, cells expressing the anti-FXI antibodies and methods for producing the anti-FXI antibodies.
Public/Granted literature
- US20190106509A1 Monoclonal antibodies against the active site of factor XI and uses thereof Public/Granted day:2019-04-11
Information query
